Enfusion, Inc. (NYSE:ENFN) Short Interest Update

Enfusion, Inc. (NYSE:ENFN) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,010,000 shares, an increase of 41.9% from the January 15th total of 711,700 shares. Currently, 2.4% of the company’s stock are sold short. Based on an average daily volume of 797,400 shares, the short-interest ratio is presently 1.3 days.

Enfusion Price Performance

Shares of NYSE:ENFN opened at $11.11 on Friday. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of 278.74, a price-to-earnings-growth ratio of 1.83 and a beta of 0.96. The business’s 50 day moving average price is $10.72 and its 200-day moving average price is $9.55. Enfusion has a 1 year low of $7.83 and a 1 year high of $11.38.

Insider Activity

In other Enfusion news, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total value of $218,664.03. Following the sale, the chief operating officer now directly owns 1,143,544 shares of the company’s stock, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Oleg Movchan sold 2,771 shares of Enfusion stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $28,070.23. Following the transaction, the chief executive officer now owns 526,702 shares of the company’s stock, valued at $5,335,491.26. The trade was a 0.52 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 57,367 shares of company stock worth $591,335. Insiders own 36.44% of the company’s stock.

Institutional Trading of Enfusion

Several institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC lifted its stake in Enfusion by 58.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 13,227 shares of the company’s stock valued at $136,000 after buying an additional 4,889 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of Enfusion by 17.3% in the fourth quarter. MetLife Investment Management LLC now owns 33,785 shares of the company’s stock valued at $348,000 after acquiring an additional 4,993 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Enfusion by 16.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 798,870 shares of the company’s stock worth $8,229,000 after acquiring an additional 110,364 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Enfusion during the fourth quarter worth approximately $1,142,000. Finally, Walleye Capital LLC acquired a new position in Enfusion in the 4th quarter valued at $341,000. Institutional investors and hedge funds own 81.05% of the company’s stock.

Analysts Set New Price Targets

ENFN has been the subject of a number of analyst reports. Piper Sandler boosted their price target on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd. William Blair reaffirmed a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Finally, Stifel Nicolaus increased their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $10.50.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.